chrisvoncsefalvay/vaers-outcomes huggingface dataset:
heartache jumped even during short walking; significantly elevated resting heart rate of 100bpm and slow walking heart rate of 125bpm and evening parking above 140bpm; shortness of breath; a bit of dizziness; heart rate during light activity feels strained; This is a spontaneous report from a contactable consumer (patient).  A 56-year-old male patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) dose 2 via an unspecified route of administration, administered in Arm Left on 08Apr2021 09:00 at age of 56-year-old (Lot Number: EW0153) as dose 2, single for covid-19 immunisation.  The patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Pfizer, Lot number EP7534) on 17Mar2021 08:00 PM at age of 56-year-old in Left arm for covid-19 immunisation. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient did not have COVID tested post vaccination and did not have COVID prior vaccination. The patient had no known allergies. The patient had no other medical history. There were no concomitant medications.  It was reported his normal resting heartrate was 65bpm. Within 6 hours of the second injection, he experienced significantly elevated resting heart rate of 100bpm and slow walking heart rate of 125bpm and evening parking above 140bpm just walking to the bathroom. This condition lasted for three days, lessening day to day. However, his resting heart rate remained higher than to the average with periods of rapid and sometimes uneven feeling heartbeat for a couple weeks. He also experienced shortness of breath and a bit of dizziness when his heartache jumped even during short walking. Currently, resting heart rate is back to his normal zone but his heart rate during light activity feels strained, with shortness of breath. The event onset date was 09Apr2021 09:00, no treatment was received, the outcome of the events was recovered with Sequel.  No follow-up attempts are possible. No further information is expected.
Employee called to report a reaction day after getting the vaccination. Employee reports symptoms starting at 3AM on 4/23/19. Symptoms include: headache, fever, cold sweats, increased/ high pulse, pressure in chest area/ chest pain. Employee states symptoms are still present.
Shortly after administration of the vaccine on 1/7/21, the patient experienced heart palpitations.  Continued all day and into the next day.  The patient contacted PCP on 1/8/21.  PCP indicated since a  recent stress test was done (12/1/20), no need for an EKG.  Per patient, PCP thinks the patient has acid reflux (actively taking omeprazole 20mg/day).    Palpitations have resolved.
Inflammatory initially with neurological symptoms after 12-14 hrs.  Unable to stand, walk, sit up or roll over in bed even with assistance
Received Moderna booster on December 8. Developed dermatographic urticaria on December 23. Dermatographic urticaria has persisted since December 23 and is ongoing. Consulted with both a dermatologist and an allergist. Allergist advised that she had seen many patients with this reaction, specifically to the COVID-19 booster. Treatment plan is Zyrtec 10mg BID until hives resolve.
Pfizer-BioNTech COVID-19 Vaccine EUA  Starting two days after injection: headache, sore throat, cough, exhaustion, some intestinal cramping
Woke up and was shaking with severe chills. Extreme total body muscle and joint aches. High blood pressure 159/100 and 120 heart rate. Body temperature ranging from 100 to 102 that lasted for 24 hours.
Onset 6pm 4/20/10 chills, nausea, fever 103, dizziness, brief syncope in bathroom. Severe epigastric pain which lessened by 4/21/10 AM, weak, nausea 4/21/10 fever resolved by 4/21/10 AM.
Warm swollen area where the shot was given. Scratchy throat and some coughing. Shot was Monday, Wednesday afternoon noticed the swollen red area. Ice and medicine.
Subsequent to receiving varicella virus vaccine live the pt developed spots on face that spread all over and blisters formed. The pt also developed a headache. Pt was treated with acetaminophen and Benadryl. The rash symptoms lasted for 7 days.
Developed bilateral DVT with right sided PE within 2 days of vaccine. Clinically stable.
I have Adenomyosis and Endometriosis but I've been in a  remission state from October 2020 - March 2021,  I had no daily pain and only have low-level pain (1-4/10) during my periods. But after the vaccine, my chronic pain and heavy bleeding came back again.  I had my vaccine second dose of vaccine on March 24, 2021.  1st period - Mar 30, 2021 - started to feel an increase in pain during the period but not that much. There was no change in bleeding volume but the bleeding length lengthened from 4 days (before the vaccine) to 7 days. 2nd period - Apr 28, 2021 - there was an increased in bleeding volume and more clots, also an increased in pain level up to 7/10. Bleeding and spotting lasted for 12 days. 3rd period - May 1, 2021 - my cycle shortened to 25 days only. The bleeding less heavy, less clots compared to April, but the pain level still up to 7/10.  Bleeding and spotting lasted for 8 days 4th period - Jun 11, 2021 - my cycle shortened to 19 days only. The bleeding was less heavy, and the pain down to around 5-6/10. The bleeding and spotting lasted for 7-8 days. 5th period - Jul 9, 2021 - 28 days cycle. Very heavy bleeding , pain level increased to 8/10 and intense fow the whole day on day 2 with no relieve from ibuprofen, cbd oil, and valerian root. I'm still bleeding at the moment making this report.  Overal, I have pain almost daily now. I only have pain free days for 1 week last month. This is bad!
Migraine, Fever of 101.9 x 8 hrs Took Ibuprofen & Acetaminophen
Fatigue; Flu-like symptoms; This case was reported by a pharmacist via call center representative and described the occurrence of fatigue in an unspecified number of adult patients who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received Shingrix at an unknown dose. On an unknown date, less than 2 years after receiving Shingrix, the patient experienced fatigue and influenza-like symptoms. On an unknown date, the outcome of the fatigue and influenza-like symptoms were unknown.   It was unknown if the reporter considered the fatigue and influenza-like symptoms to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not applicable for this report. The age group of the patient was not reported, but selected as an adult as per vaccine indication. The pharmacist reported that, the patient reported fatigue and flu like symptoms. The reporter did not provide number of patients and vaccine details. The reporter consented to follow up.
Arm was hot for 3 days and very sore, Lungs are very sensitive when taking deep breathes and exercising also hurts lungs, coughing up mucous in the mornings, lethargic and tired after the shot, intense intolerance or allergic reactions to alcohol (face and chest becomes red and trouble breathing becomes more acute).
Full body hives (neck, chest, arms, upper back), extreme body aches,  fever of 103, migraine, and couldn't lift my arm for  days (beyond normal soreness after other vaccines).  Symptoms lasted 4 days.   When I went to get my booster shot, the clinic manager from the state said that it was too risky to get booster, so  I was denied because of hives reaction.   My doctor said the same thing and I'm currently being referred to allergy center in my region.
Running eye, slurred speech, drooping of left side of face. Symptoms appeared appx. 72 Hrs. after flu shot.     CAT scan to rule out stroke.   Famvir 500mg for virus, AKWA tears for eye problem. Medical record states pain. msv
blanching macular rash about 15 minutes later. mostly on trunk and some on legs/arms.  no hives.
Severe Thrombocytopenia Platelet Count 2000, presumed ITP
sore arm; Headache; Chills; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (sore arm), HEADACHE (Headache) and CHILLS (Chills) in a 58-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 027L20A) for COVID-19 vaccination.     The patient's past medical history included No adverse event.    On 04-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 05-Mar-2021, the patient experienced PAIN IN EXTREMITY (sore arm), HEADACHE (Headache) and CHILLS (Chills). At the time of the report, PAIN IN EXTREMITY (sore arm), HEADACHE (Headache) and CHILLS (Chills) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Reporter did not allow further contact
This spontaneous case was reported by a consumer and describes the occurrence of DYSPNEA (Heavy breathing), FLUSHING (hot face), DIZZINESS (Dizzy) and SWELLING FACE (face is still semi swollen) in a 43-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. No Medical History information was reported. On 21-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 21-Apr-2021, the patient experienced DYSPNEA (Heavy breathing), FLUSHING (hot face), DIZZINESS (Dizzy) and SWELLING FACE (face is still semi swollen). At the time of the report, DYSPNOEA (Heavy breathing), FLUSHING (hot face), DIZZINESS (Dizzy) and SWELLING FACE (face is still semi swollen) outcome was unknown. Not Provided. The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.
Subject 1-07-03285 is a nearly 19 year old G2P1 female who was initially seen in the emergency room on 05Feb2008 for 1 day history of sporadic vaginal bleeding with no other symptoms. Her last menstrual period was 20Dec2007. Her human chorionic gonadotropin (HCG) level was 18,638 units/ml, which is consistent with 4 to 5 weeks gestation. An ultrasound revealed an intrauterine pregnancy. Urine analysis was negative for trichomonas by wet mount but positive by PCR. Her urine analysis was also negative for yeast and positive for clue cells and moderate amount of WBC. She was diagnoses with a threatened miscarriage and was sent home for follow-up in one week. Her specimen from the cervix was reported positive on 07Feb2008 for Chlamydia trachomatis by PCR and was negative for Neisseria gonorrhoeae. Subject was again seen in the ER on 11Feb2008 for daily vaginal bleeding of approximately 1 pad/day. She complained of mild suprapubic cramping. Repeat ultrasound showed an irregular yolk sac contour and a fetal pole that was not visualized. Mean gestational sac measurement corresponded to a 7 week gestation. Her HCG increased to 20,000 units/ml. These observations were consistent with nonviable pregnancy and impending miscarriage. She was sent home and instructed to take prenatal vitamins and avoid cigarette smoke. Repeat cervical test for GC and Chlamydia was again positive for Chlamydia trachomatis by PCR. The subject was seen in the ER on 03Mar2008 for vaginal discharge irritation and for treatment of her positive Chlamydia trachomatis test. Her HCG level was 8 consisted with a nonpregnant state. An ultrasound did not reveal an intrauterine pregnancy. Subject was treated with rocephin 250 mg IM and one gram oral dose of zithromax.   Final diagnosis: Complete Miscarriage Secondary: Chlamydia trachomatis cervicitis  Past Medical History: none Medication: none.  Date of Last Menstrual Period: 20 Dec 2007   Influenza vaccine: FluMist Date of Vaccination: 21 Nov 2007 Date of Birth: 13 Feb 1989 Date of SAE:  March 3, 2008 SAE: Serious and unexpected. SAE not related to FluMist.
Persistent shoulder soreness ever since receiving the vaccine.  Patient complains of occasional "shooting pains down her arm".
This is a solicited report received from contactable reporter(s) (Consumer or other non-HCP). The reporter is the patient. Other Case identifier(s): 22K-163-4459126-00.  A 65-year-old female patient received BNT162b2 (BNT162B2), as dose number unknown, single (Batch/Lot number: unknown) intramuscular for covid-19 immunisation; adalimumab (HUMIRA), (Batch/Lot number: unknown) at unk (citrate free), subcutaneous for Crohn's disease (Moderate to severe adult Crohn's disease). The patient's relevant medical history and concomitant medications were not reported. The following information was reported: Pulmonary Thrombosis (medically significant), outcome "recovered", described as "Blood clot in lung"; Haematochezia (medically significant), outcome "recovered", described as "Blood in stool". The action taken for adalimumab was unknown. The reporter's assessment of the causal relationship of "blood clot in lung" and "blood in stool" with the suspect product(s) BNT162b2 was not provided at the time of this report. Since no determination has been received, the case is managed based on the company causality assessment. Additional information: Events of blood clot in lung and non-serious blood in stool with Humira (Adalimumab). On unknown dates, the patient experienced blood clot in lung and non-serious blood in stool. On unknown dates, blood clot in lung and non-serious blood in stool resolved. Pfizer BioNTech COVID-19 Vaccine (Tozinameran) was also considered suspect. The patient had blood in stool and sometimes could not go to the bathroom. She had blood clot in lung. It was unknown if patient was enrolled in a Covid-19 Vaccine Trial. Primary reporter did not have the lot number information, because the information was not available in the patient's file.  Causality for Humira (Adalimumab): The reporter's causality for the event(s) of C blood clot in lung and non-serious blood in stool with Humira (Adalimumab) was no reasonable possibility. AbbVie's opinion is that the event of blood clot in lung is not assessable. AbbVie's opinion is that there is no reasonable possibility that the event of blood in stool is related to Humira (Adalimumab). Causality for Pfizer BioNTech Covid-19 Vaccine (Tozinameran): The reporter's causality for the event(s) of C blood clot in lung and non-serious blood in stool with Pfizer BioNTech Covid-19 Vaccine (Tozinameran) was Possible.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.; Sender's Comments: Based on the information provided in the narrative , a possible contributory role of the suspect vaccine  to reported event of  blood clot in lung and  blood in stool  cannot be excluded.
Injection sight slightly warm but not red.  But under armpit it is sore and swollen.
This is a spontaneous report from a contactable nurse via Pfizer sales representative. A 18-year-old female patient received the second dose of TRUMENBA, on an unspecified date at single dose for immunisation.  Medical history included ongoing vitiligo.  The patient's concomitant medications were not reported.  The first dose of meningococcal group b rlp2086 was given on 30Aug2016 and no event occurred. The patient experienced severe chills, nausea and needed to sit down putting head between knees and looked pale/ill, on an unspecified date, after three hours of receiving 2nd vaccine dose.  The outcome of the events was unknown.
Service member is a 49 year old patient who experienced several episodes chest pains described as pressure several times approximately 6 weeks after receiving Anthrax #3. He recalls feeling tired, having a rapid resting heart rate (90) and wispy breath for 3-4 days after receiving his first anthrax injection (he also received Td and Influenza at the same time). On 3/20 he developed a cough productive for yellow phlegm and a burning pain in his mid chest that increased when he was lying down and decreased when when he was up and active. He sought medical care and was treated with Cipro. By 3/28 he reports having increasing fatigue and SOB. On 3/31 he experienced severe upper chest pains with radiation to his back and SOB. He sought aid and was treated with NTG, pain medication and evacuated to a hospital. On 4/2 he was admitted where an admission EKG revealed evidence of a recent anterior wall STEMI. He was given standard therapy and immediately referred for mechanical reperfusion. This was accomplished with PTCA and stent deployment within the proximal left anterior descending coronary artery. He was evacuated on 4/8 with recommendations for continued medical care and cardiac rehab.  He continues to have periodic episodes of sharp chest pains that are usually located in his left armpit and sometimes up into left neck. Additionally, he complained of left hip pains.
3 minutes after injection my tongue tasted like metal. 5 minutes after tingling lips. 15 minutes after heartburn . Next morning stomached burning for 5 days. Every joint in my fingers were painful. My hands were slightly swollen.  The second shot  caused fever shaking for 4. Hours 102 degrees. Every joint in my body painful. My hand were very swollen for 4 months. All my joints are still painful. Hands still slightly swollen. My tongue still tastes metallic.  Are theses side effects ever going to go away ?
COVID 19 Treatment; COVID 19 Treatment; This is a spontaneous report received from a contactable reporter(s) (Physician).  A 67-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), in Mar2022 as dose 4 (booster), single (Batch/Lot number: unknown) at the age of 68 years for covid-19 immunisation; covid-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown) and as dose 3 (booster) single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "aspiration pneumonia on admission" (unspecified if ongoing), notes: aspiration pneumonia on admission; hypothyroid; "hypothyroid" (unspecified if ongoing), notes: aspiration pneumonia on admission; hypothyroid. There were no concomitant medications.  The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "COVID 19 Treatment". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Unknown results, notes: COVID 19 Treatment; Positive. Therapeutic measures were taken as a result of vaccination failure, covid-19. No other medication reported in 2 weeks.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.; Sender's Comments: Based on the information provided, known drug safety profile and plausible temporal association, the causality between BNT162B2 and vaccination failure, Covid 19 cannot be completely excluded.
got shingles after getting the vaccines/suspected vaccination failure; shingles; This case was reported by a consumer via interactive digital media and described the occurrence of vaccination failure in a male patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received Shingles vaccine. On an unknown date, unknown after receiving Shingles vaccine, the patient experienced vaccination failure (serious criteria GSK medically significant) and shingles. On an unknown date, the outcome of the vaccination failure and shingles were unknown.   It was unknown if the reporter considered the vaccination failure and shingles to be related to Shingles vaccine.     Additional Information: GSK receipt date: 1-June-2022 Reporter's comment:  This case was reported by a patient's wife via interactive digital media. The reporter stated that her husband also got shingles after getting the vaccines a few years ago. Additional Supportive Information: This case was considered as suspected vaccination failure since the details regarding completion of primary vaccination schedule, time to onset and laboratory confirmation of shingles was not provided. Note: The pain was not coded as event since from the narrative it seems that the patient did not experienced pain.
This is a spontaneous report from a contactable healthcare professional via a Pfizer sales representative. A 19-year-old female patient received TRUMENBA via an unspecified route of administration on an unspecified date at a single dose for immunization. The patient's medical history and concomitant medications were not reported. On an unspecified date, the patient experienced nausea, low grade fever, and body ache. It was reported that the patient was healthy. She had just gotten NORPLANT since her last visit. Outcome of the events was unknown. No follow-up attempts are possible, information about batch number cannot be obtained. No further information is expected.
I experienced the usual side effects of headache, fatigue and fever. However, approximately 4 hours after getting the vaccination, my left hand became numb starting at the fingertips and progressively worsened up to slightly past my left wrist. I experienced some parathesia in my right hand approximately 6-8hrs after the shot, but never became numb. The numbness in my left hand lasted approximately 4 hours and then changed into parathesia with some tingling sensation. by the morning everything was fine.
Patient presented to the ED and was subsequently hospitalized within 6 weeks of receiving COVID vaccination for new onset atrial fibrillation.
Information has been received from a nurse concerning several female patients who were vaccinated with doses Gardasil.  Subsequently the patients developed injection site pain.  Unspecified medical attention was sought.  At the time of the report the patients' outcomes were unknown.  Additional information has been requested.
Narrative:  Pt is a 89y.o male who died on 03/02/2021 w/ h/o dementia, prostate cancer, BCC,BPH, HLD, gout. Pt received Moderna Covid-19 Vaccination 1/2 on 01/08/2021. Pt died at home on 03/02/2021. Unlikely that Moderna Covid-19 vaccine caused/contributed to pt death.
Expired Flulaval administred; This case was reported by a other health professional via call center representative and described the occurrence of expired vaccine used in a 79-year-old female patient who received Flu Seasonal QIV Quebec (FluLaval Quadrivalent 2022-2023 season) (batch number 24Bm2, expiry date 30th June 2022) for prophylaxis.   Co-suspect products included flu seasonal qiv quebec pre-filled syringe device (Flulaval Tetra Pre-Filled Syringe Device) injection syringe for prophylaxis.   On 19th October 2022, the patient received FluLaval Quadrivalent 2022-2023 season and Flulaval Tetra Pre-Filled Syringe Device. On 19th October 2022, unknown after receiving FluLaval Quadrivalent 2022-2023 season and Flulaval Tetra Pre-Filled Syringe Device, the patient experienced expired vaccine used. On an unknown date, the outcome of the expired vaccine used was unknown.     This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK receipt date: 20-Oct-2022 Reporter's comment: The reporter consented to follow-up via email. Additional supportive information: The patient received an expired dose of Flulaval one day before the reporting date, which led to expired vaccine used.
Child developed a rash with in 24 hours after receiving vaccines.  Rash started on the trunk with no other accompanying signs and ssymptoms.  Instructed per doctor's orders for parent to give Benadryl 1 3/4 to 2 tsp TID for 5 days. Call clinic or go to ER if symptoms worsens.
Patient was given a dose of ROTATEQ today at well child visit which would have been her third dose of the vaccine. Had one given on 09/07/2017.
I woke up with a sore throat and a rash on my chest. Four hours later, the rash was all over my waist, abdomen, back, neck, and ears as well. By the next morning, the rash was everywhere from my ankles and to the top of my head. The rash cleared up in three days.
Itchy head to toe rash that began the day after second dose. took oral benadryl & applied anti itch cream & symptoms lasted 8 days
12 days of arm soreness- no redness - when she presses on site of injection.
Erythema & swelling approx 2' inferior to chromium process extending to just superior of antecubital space. Tenderness to touch, Left upper arm.